Associations of anogenital low-risk human papillomavirus infection with cancer and acquisition of HIV

Sexually Transmitted Diseases

Volumn 42, Issue 10, 2015, Pages 541-544

  Bennetts, Liga E ^a   Wagner, Monika ^a   Giuliano, Anna R ^b   Palefsky, Joel M ^c   Steben, Marc ^d   Weiss, Thomas W ^e  

^a LASER Analytica   (Canada)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d INSTITUT NATIONAL DE SANTÉ PUBLIQUE DU QUÉBEC   (Canada)

^e MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANOGENITAL LOW RISK HUMAN PAPILLOMAVIRUS INFECTION; CANCER RISK; CONDYLOMA ACUMINATUM; DISEASE ASSOCIATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MIXED INFECTION; NEOPLASM; NONHUMAN; PAPILLOMAVIRUS INFECTION; REVIEW; VIRUS TRANSMISSION; ANUS TUMOR; COMPLICATION; FEMALE; FEMALE GENITAL TRACT TUMOR; HIV INFECTIONS; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; MALE; MALE GENITAL TRACT TUMOR; PAPILLOMAVIRIDAE; PATHOGENICITY; PATHOLOGY; PROSPECTIVE STUDY; RISK FACTOR; VIROLOGY;

ANUS NEOPLASMS; COINFECTION; CONDYLOMATA ACUMINATA; FEMALE; GENITAL NEOPLASMS, FEMALE; GENITAL NEOPLASMS, MALE; HIV INFECTIONS; HUMANS; IMMUNOCOMPROMISED HOST; MALE; PAPILLOMAVIRIDAE; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 84941760693     PISSN: 01485717     EISSN: 15374521     Source Type: Journal    
DOI: 10.1097/OLQ.0000000000000319     Document Type: Review

References (54)

1. International Agency for Research on Cancer. IARC monographs on the evaluation of carcinogenic risks to humans.Monograph on Human Papillomaviruses. Vol 90. Lyon, France: International Agency for Research on Cancer; 2007; 90:1-179.
2. Bernard HU, Burk RD, Chen Z, et al. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology 2010;401:70-79.
3. International Agency for Research on Cancer. Human papillomaviruses. IARC Monographs. 2012:255-313. Available at: http://monographs.iarc. fr/ENG/Monographs/vol100B/mono100B-11.pdf.AccessedMay 3, 2013.
4. Schiffman M, Clifford G, Buonaguro FM. Classification of weakly carcinogenic human papillomavirus types: Addressing the limits of epidemiology at the borderline. Infect Agent Cancer 2009;4:8.
5. Castle PE. The evolving definition of carcinogenic human papillomavirus. Infect Agent Cancer 2009;4:7.
6. Srodon M, Stoler MH, Baber GB, et al. The distribution of low and high-risk HPV types in vulvar and vaginal intraepithelial neoplasia (VIN and VaIN). Am J Surg Pathol 2006;30:1513-1518.
7. Hoots BE, Palefsky JM, Pimenta JM, et al. Human papillomavirus type distribution in anal cancer and anal intraepithelial lesions. Int J Cancer 2009;124:2375-2383.
8. D'Hauwers KW, Depuydt CE, Bogers JJ, et al. Human papillomavirus, lichen sclerosus and penile cancer: A study in Belgium. Vaccine 2012; 30:6573-6577.
9. Clifford G, Franceschi S, Diaz M, et al. Chapter 3: HPV typedistribution in women with and without cervical neoplastic diseases. Vaccine 2006;24(suppl 3):S3/S26-S34.
10. Kim KM, Cho NH, Choi HS, et al. Effect of human papilloma virus expression on clinical course of laryngeal papilloma. Acta Otolaryngol 2008;128:1138-1144.
11. Makiyama K, Hirai R, Matsuzaki H, et al. Assessment of human papilloma virus infection in adult laryngeal papilloma using a screening test. J Voice 2013;27:230-235.
12. Hawkins MG, Winder DM, Ball SL, et al. Detection of specific HPV subtypes responsible for the pathogenesis of condylomata acuminata. Virol J 2013;10:137.
13. Lacey CJ, Lowndes CM, Shah KV. Chapter 4: Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine 2006;24(suppl 3):S3/35-S3/41.
14. Garland SM, Steben M, Sings HL, et al. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J Infect Dis 2009;199:805-814.
15. Patel H, Wagner M, Singhal P, et al. Systematic review of the incidence and prevalence of genital warts. BMC Infect Dis 2013;13:39.
16. Raymakers AJ, Sadatsafavi M, Marra F, et al. Economic and humanistic burden of external genital warts. Pharmacoeconomics 2012;30:1-16.
17. Sherman KJ, Daling JR, Chu J, et al. Genital warts, other sexually transmitted diseases, and vulvar cancer. Epidemiology 1991;2:257-262.
18. Sigurgeirsson B, Lindelöf B, Eklund G. Condylomata acuminata and risk of cancer: An epidemiological study. BMJ 1991;303:341-344.
19. Friis S, Kjaer SK, Frisch M, et al. Cervical intraepithelial neoplasia, anogenital cancer, and other cancer types in women after hospitalization for condylomata acuminata. J Infect Dis 1997;175:743-748.
20. Sinha P, Logan HL, Mendenhall WM. Human papillomavirus, smoking, and head and neck cancer. Am J Otolaryngol 2012;33:130-136.
21. Castellsagué X, Muñoz N. Chapter 3: Cofactors in human papillomavirus carcinogenesis-Role of parity, oral contraceptives, and tobacco smoking. J Natl Cancer Inst Monogr 2003: 20-28.
22. Giuliano AR, Sedjo RL, Roe DJ, et al. Clearance of oncogenic human papillomavirus (HPV) infection: Effect of smoking (United States). Cancer Causes Control 2002;13:839-846.
23. Wei L, Gravitt PE, Song H, et al. Nitric oxide induces early viral transcription coincident with increased DNA damage and mutation rates in human papillomavirus-infected cells. Cancer Res 2009;69: 4878-4884.
24. Wittekindt C,Wagner S,Mayer CS, et al. Basics of tumor development and importance of human papilloma virus (HPV) for head and neck cancer. GMS Curr Top Otorhinolaryngol Head Neck Surg 2012;11: Doc09.
25. Nordenvall C, Chang ET, Adami HO, et al. Cancer risk among patients with condylomata acuminata. Int J Cancer 2006;119:888-893.
26. Blomberg M, Friis S, Munk C, et al. Genital warts and risk of cancer: A Danish study of nearly 50 000 patients with genital warts. J Infect Dis 2012;205:1544-1553.
27. Kjaer SK, Dahl C, Engholm G, et al. Case-control study of risk factors for cervical neoplasia in Denmark. II. Role of sexual activity, reproductive factors, and venereal infections. Cancer Causes Control 1992;3: 339-348.
28. Madsen BS, Jensen HL, van den Brule AJ, et al. Risk factors for invasive squamous cell carcinoma of the vulva and vagina-Population-based case-control study in Denmark. Int J Cancer 2008;122:2827-2834.
29. Madsen BS, van den Brule AJ, Jensen HL, et al. Risk factors for squamous cell carcinoma of the penis-Population-based case-control study in Denmark. Cancer Epidemiol Biomarkers Prev 2008;17:2683-2691.
30. Tseng HF, Morgenstern H, Mack T, et al. Risk factors for penile cancer: Results of a population-based case-control study in Los Angeles County (United States). Cancer Causes Control 2001;12:267-277.
31. Daling JR, Madeleine MM, Schwartz SM, et al. A population-based study of squamous cell vaginal cancer: HPV and cofactors. Gynecol Oncol 2002;84:263-270.
32. del Pino M, BleekerMC, QuintWG, et al. Comprehensive analysis of human papillomavirus prevalence and the potential role of low-risk types in verrucous carcinoma. Mod Pathol 2012;25:1354-1363.
33. Bergeron C, Ronco G, Reuschenbach M, et al. The clinical impact of using p16(INK4a) immunochemistry in cervical histopathology and cytology: An update of recent developments. Int J Cancer 2015;136: 2741-2751.
34. Garret M. Relationship of podophyllin to carcinogenesis. A comparison of cytologic and histologic changes induced by podophyllin in the mouse cervix with those induced by 3,4 benzpyrene. Cancer 1966;19:947-958.
35. Kaminetzky HA, McGrew EA, Phillips RL. Experimental cervical epithelial dysplasia. Obstet Gynecol 1959;14:1-10.
36. Kaminetzky HA, McGrew EA. Podophyllin and mouse cervix. Effect of long-term application. Arch Pathol 1962;73:481-485.
37. Roe FJ, Salaman MH. Further studies on incomplete carcinogenesis: Triethylene melamine (T.E.M.), 1,2-benzanthracene and betapropiolactone, as initiators of skin tumour formation in the mouse. Br J Cancer 1955;9:177-203.
38. Longstaff E, von Krogh G. Condyloma eradication: self-therapy with 0.15-0.5% podophyllotoxin versus 20-25% podophyllin preparations- An integrated safety assessment. Regul Toxicol Pharmacol 2001;33: 117-137.
39. Taper HS. Induction of the deficient acid DNAse activity in mouse interfollicular epidermis by croton oil as a possible tumor promoting mechanism. Z Krebsforsch Klin Onkol Cancer Res Clin Oncol 1977; 90:197-210.
40. International Agency for Research on Cancer (IARC). IARC Monographs. Trichloroacetic acid. 2014; 106:393-437. Available at: http://monographs.iarc.fr/ENG/Monographs/vol106/. Accessed April 9, 2015.
41. Anic GM, Lee JH, Stockwell H, et al. Incidence and human papillomavirus (HPV) type distribution of genital warts in a multinational cohort of men: The HPV in Men Study. J Infect Dis 2011;204:1886-1892.
42. van der Loeff MF, Nyitray AG, Giuliano AR. HPV vaccination to prevent HIV infection: time for randomized controlled trials. Sex Transm Dis 2011;38:640-643.
43. Houlihan CF, Larke N, Watson-Jones D, et al. HPV infection & increased risk of HIV acquisition. A systematic review & meta-analysis. Poster presentation at the XIX International AIDS Conference; July 22-27, 2012; Washington, DC. 2012.
44. Averbach SH, Gravitt PE, Nowak RG, et al. The association between cervical human papillomavirus infection and HIV acquisition among women in Zimbabwe. AIDS 2010;24:1035-1042.
45. Smith-McCune KK, Shiboski S, Chirenje MZ, et al. Type-specific cervico-vaginal human papillomavirus infection increases risk of HIV acquisition independent of other sexually transmitted infections. PLoS One 2010;5:e10094.
46. Tobian AA, Grabowski MK, Kigozi G, et al. Human papillomavirus clearance among males is associated with HIVacquisition and increased dendritic cell density in the foreskin. J Infect Dis 2013;207:1713-1722.
47. Auvert B, Lissouba P, Cutler E, et al. Association of oncogenic and nononcogenic human papillomavirus with HIV incidence. J Acquir Immune Defic Syndr 2010;53:111-116.
48. Coleman N, Birley HD, Renton AM, et al. Immunological events in regressing genital warts. Am J Clin Pathol 1994;102:768-774.
49. Woo YL, Sterling J, Damay I, et al. Characterising the local immune responses in cervical intraepithelial neoplasia: A cross-sectional and longitudinal analysis. BJOG 2008;115:1616-1621.
50. Nicholls PK,Moore PF, Anderson DM, et al. Regression of canine oral papillomas is associated with infiltration of CD4+ and CD8+ lymphocytes. Virology 2001;283:31-39.
51. Handisurya A, Day PM, Thompson CD, et al. Strain-specific properties and T cells regulate the susceptibility to papilloma induction by Mus musculus papillomavirus 1. PLoS Pathog 2014;10:e1004314.
52. de Jong MA, Geijtenbeek TB. Human immunodeficiency virus-1 acquisition in genital mucosa: Langerhans cells as key-players. J Intern Med 2009;265:18-28.
53. Schim van der Loeff MF, Giuliano AR. Human papillomavirus vaccination: Component of an integrated HIV prevention program? AIDS 2012;26:2251-2252.
54. Lissouba P, Van de Perre P, Auvert B. Association of genital human papillomavirus infection with HIV acquisition: A systematic review and meta-analysis. Sex Transm Infect 2013;89:350-356.